BUDGET IMPACT ANALYSIS OF SOUVENAID FOR THE MANAGEMENT OF ALZHEIMER'S DISEASE IN MIDDLE EAST AND NORTH AFRICA REGION
Author(s)
Mohammed Almotiri, MD1, Abdel Naseer Maged, MD2, Mohamed Shawky Khater, MD3, Hind Aljarallaha, B.H.Sc.4, Yazed Alruthia, BSc, PharmD, PhD5, Kotb Habib, Family Medicine6, Amir Ahmed, MD7, Mohammed Gamil Elnoamani, Doctorate in geriatric medicine8, Hazem Elsayed Hussien Mohammed, MD9, Ahmed Abdelmawla, MBA10, Fardous A. Mustafa, MBA11, Pratik Ramesh Dhopte, MPH12, Rita Ojeil, MASc13.
1Ministry of Interior, Riyadh, Saudi Arabia, 2Cairo University, Cairo, Egypt, 3Ain Shams University, Cairo, Egypt, 4Sultan Bin Abdulaziz Humanitarian City Riyadh, Riyadh, Saudi Arabia, 5King Saud University, Riyadh, Saudi Arabia, 6Saud Al-Babtain Center for Cardiac Medicine and Surgery, Dammam Health Network, Eastern Health Clust, Dammam, Saudi Arabia, 7Gulf University, Ajman, United Arab Emirates, 8Dubai Health Authority, Dubai, United Arab Emirates, 9Obaidallah Geriatric Hospital, Ras Al-Khaimah, United Arab Emirates, 10Danone, Dubai, United Arab Emirates, 11Danone, Cairo, Egypt, 12PDC-CRO, Pune, India, 13PDC-CRO, Dubai, United Arab Emirates.
1Ministry of Interior, Riyadh, Saudi Arabia, 2Cairo University, Cairo, Egypt, 3Ain Shams University, Cairo, Egypt, 4Sultan Bin Abdulaziz Humanitarian City Riyadh, Riyadh, Saudi Arabia, 5King Saud University, Riyadh, Saudi Arabia, 6Saud Al-Babtain Center for Cardiac Medicine and Surgery, Dammam Health Network, Eastern Health Clust, Dammam, Saudi Arabia, 7Gulf University, Ajman, United Arab Emirates, 8Dubai Health Authority, Dubai, United Arab Emirates, 9Obaidallah Geriatric Hospital, Ras Al-Khaimah, United Arab Emirates, 10Danone, Dubai, United Arab Emirates, 11Danone, Cairo, Egypt, 12PDC-CRO, Pune, India, 13PDC-CRO, Dubai, United Arab Emirates.
OBJECTIVES: Alzheimer’s disease (AD) is a progressive neurodegenerative disease. In the Middle East and North Africa (MENA), AD burden is rising with aging populations, with a prevalence of ~773 per 100,000, >$10 billion economic impact, and significant reliance on informal caregiving. Souvenaid is a food for special medical purposes for the dietary management of early AD. This study evaluates the societal and providers-level budgetary and health impact of souvenaid as an add-on therapy in early AD over five years.
METHODS: A population-based budget impact model compared souvenaid with standard care in patients with early AD. Costs and outcomes were assessed from public and private sector perspectives. Key inputs included market share, clinical efficacy, direct and indirect costs, utilities, and disutilities. Outcomes included total costs, budget impact, years of life lost (YLL), years lived with disability (YLD), and disability-adjusted life years (DALYs).
RESULTS: The five-year budget impact of introducing souvenaid as an add-on therapy in the Kingdom of Saudi Arabia (KSA) and the United Arab Emirates (UAE) was SAR -16.26M and SAR -17.85M; and AED -0.007 and AED -10.59M, for public and private providers, respectively. For Egypt, it was EGP -1.73M for public providers. Overall monetary loss due to DALYs decreased by SAR 7.5M and SAR 3.79M in KSA; AED 0.43M and AED 2.74M in UAE; and EGP 1.01M in Egypt. One-way sensitivity analyses indicated that budget impact is mainly driven by drug acquisition costs, while clinical factors such as fracture risk and treatment efficacy contribute relatively smaller financial variability.
CONCLUSIONS: Souvenaid incurs additional acquisition costs as an add-on therapy, but these are offset by reduced expenses for complications, health state management, and adverse events. Overall, it delivers a favorable budget impact, enabling sustainable adoption without increasing total healthcare spending, while supporting cost efficiency and aligning with value-based healthcare goals.
METHODS: A population-based budget impact model compared souvenaid with standard care in patients with early AD. Costs and outcomes were assessed from public and private sector perspectives. Key inputs included market share, clinical efficacy, direct and indirect costs, utilities, and disutilities. Outcomes included total costs, budget impact, years of life lost (YLL), years lived with disability (YLD), and disability-adjusted life years (DALYs).
RESULTS: The five-year budget impact of introducing souvenaid as an add-on therapy in the Kingdom of Saudi Arabia (KSA) and the United Arab Emirates (UAE) was SAR -16.26M and SAR -17.85M; and AED -0.007 and AED -10.59M, for public and private providers, respectively. For Egypt, it was EGP -1.73M for public providers. Overall monetary loss due to DALYs decreased by SAR 7.5M and SAR 3.79M in KSA; AED 0.43M and AED 2.74M in UAE; and EGP 1.01M in Egypt. One-way sensitivity analyses indicated that budget impact is mainly driven by drug acquisition costs, while clinical factors such as fracture risk and treatment efficacy contribute relatively smaller financial variability.
CONCLUSIONS: Souvenaid incurs additional acquisition costs as an add-on therapy, but these are offset by reduced expenses for complications, health state management, and adverse events. Overall, it delivers a favorable budget impact, enabling sustainable adoption without increasing total healthcare spending, while supporting cost efficiency and aligning with value-based healthcare goals.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA8
Topic
Clinical Outcomes, Economic Evaluation, Health Technology Assessment
Disease
Mental Health (including addiction), No Additional Disease & Conditions/Specialized Treatment Areas, Nutrition